Anti-inflammatory Cells in Peritoneal Cavity
Anti-inflammatory Cells in Peritoneal Cavity
Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to
 control auto-immune diseases and transplant reject. In mice, the main source of those
 anti-inflammatory lymphocytes is the peritoneal cavity. No data are available in human. This
 study aims at exploring the presence of those anti-inflammatory lymphocytes in human
 peritoneal cavity and at determine how to expand those cells.
B cells will be collected during procedures planned for patients' standard care. Peritoneal
 fluid and peripheral blood of patients will be collected during coelioscopy for exploration
 of ovarian cysts or dialysis for treatment of chronic renal insufficiency.

 Regulatory B cells (Breg cells) will be measured in peritoneal fluid and in peripheral blood
 after in vitro stimulation and assessment of intracellular interleukin-10 by flow cytometry.
 Proportion of Breg cells among B cells will be compared between peritoneal fluid and
 peripheral blood in both groups.

 Different protocols to induce differentiation of B cells into Breg cells will be tested and
 compared.
Inclusion criteria:

 -  woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy

 -  patient with chronic renal insufficiency undergoing peritoneal dialysis

 -  informed consent obtained

 Exclusion criteria:

 -  pregnancy or breast-feeding

 -  non affiliation to health care insurance

 -  treatment with corticosteroids over 15 mg/day

 -  treatment with rituximab